Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - cefuroxime axetil - film coated tablet - 125 base milligrams

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - cefuroxime axetil - film coated tablet - 500 base milligrams

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - cefuroxime axetil - film coated tablet - 250 base milligrams

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - cefuroxime as sodium salt - powder for solution or suspension for injection or infusion - cefuroxime as sodium salt 750 mg - cefuroxime - cefuroxime - cefuroxime -fresenius is indicated for the treatment of the infections listed below in adults and children, including neonates (from birth).• community acquired pneumonia• acute exacerbations of chronic bronchitis• complicated urinary tract infections, including pyelonephritis• soft-tissue infections: cellulitis, erysipelas and wound infections• intra-abdominal infections • prophylaxis against infection in gastrointestinal (including oesophageal), orthopaedic, cardiovascular, and gynaecological surgery (including caesarean section)• nose infections for example, sinusitis• septic arthritis

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - cefuroxime as sodium salt - powder for solution for inj/inf - cefuroxime as sodium salt 1500 mg - cefuroxime - cefuroxime - cefuroxime -fresenius is indicated for the treatment of the infections listed below in adults and children, including neonates (from birth).• community acquired pneumonia• acute exacerbations of chronic bronchitis• complicated urinary tract infections, including pyelonephritis• soft-tissue infections: cellulitis, erysipelas and wound infections• intra-abdominal infections • prophylaxis against infection in gastrointestinal (including oesophageal), orthopaedic, cardiovascular, and gynaecological surgery (including caesarean section)• nose infections for example, sinusitis• septic arthritis

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticali inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 500 mg - cefuroxime axetil tablets usp are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes . limitations of use cefuroxime axetil tablets usp are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae, haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes . cefuroxime axetil tablets usp are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-moderate acute bacterial maxillary sinusitis caused by susceptible strains of streptococcus pneumoniae or haemophilus influenzae (non- β-lactamase–producing strains only). limitations of use the effectiveness of cefuroxime axetil tablets usp for sinus infections caused by β-la

United States - English - NLM (National Library of Medicine)

wockhardt usa llc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 125 mg - cefuroxime axetil tablets, usp are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes . limitations of use - the efficacy of cefuroxime axetil tablets, usp in the prevention of rheumatic fever was not established in clinical trials. - the efficacy of cefuroxime axetil tablets, usp in the treatment of penicillin-resistant strains of streptococcus pyogenes has not been demonstrated in clinical trials. cefuroxime axetil tablets, usp are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus  pneumoniae , haemophilus influenzae (including β- lactamase-producing strains), moraxella catarrhalis (including β- lactamase-producing strains), or streptococcus pyogenes. cefuroxime axetil tablets, usp are indicated for the treatment of adu

United States - English - NLM (National Library of Medicine)

wockhardt limited - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 125 mg - cefuroxime axetil tablets, usp are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes . limitations of use - the efficacy of cefuroxime axetil tablets, usp in the prevention of rheumatic fever was not established in clinical trials. - the efficacy of cefuroxime axetil tablets, usp in the treatment of penicillin-resistant strains of streptococcus pyogenes has not been demonstrated in clinical trials. cefuroxime axetil tablets, usp are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus  pneumoniae , haemophilus influenzae (including β- lactamase-producing strains), moraxella catarrhalis (including β- lactamase-producing strains), or streptococcus pyogenes. cefuroxime axetil tablets, usp are indicated for the treatment of adu

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - cefuroxime sodium (unii: r8a7m9my61) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 750 mg - cefuroxime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - lower respiratory tract infections , including pneumonia, caused by streptococcus pneumoniae, haemophilus influenzae (including ampicillin-resistant strains), klebsiella spp., staphylococcus aureus (penicillinase- and non-penicillinase- producing strains), streptococcus pyogenes , and escherichia coli . - urinary tract infections caused by escherichia coli and klebsiella spp. - skin and skin structure infections caused by staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), streptococcus pyogenes , escherichia coli, klebsiella spp., and enterobacter spp. - septicemia caused by staphylococcus aureus (penicillinase- and non-penicillinase- producing strains), streptococcus pneumoniae, escherichia coli, haemophilus influenzae (including ampicillin-resistant strains), and klebsiella spp. - men

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - cefuroxime sodium (unii: r8a7m9my61) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 750 mg - cefuroxime for injection is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - lower respiratory tract infections , including pneumonia, caused by streptococcus pneumoniae , haemophilus influenzae (including ampicillin-resistant strains), klebsiella spp., staphylococcus aureus (penicillinase- and non–penicillinase-producing strains), streptococcus pyogenes , and escherichia coli . - urinary tract infections caused by escherichia coli and klebsiella spp. - skin and skin­-structure infections caused by staphylococcus aureus (penicillinase- and non–penicillinase-producing strains), streptococcus pyogenes , escherichia coli , klebsiella spp., and enterobacter spp. - septicemia caused by staphylococcus aureus (penicillinase- and non–penicillinase-producing strains), streptococcus pneumoniae , escherichia coli , haemophilus influenzae (including ampicillin-resistant strains), and klebsiella spp. - mening